Science

Jenny Seligmann: Time to re-think targeted agents in LACC/LARC

Jenny Seligmann/yorkshirecancerresearch.org.uk

Jan 14, 2025, 12:52

Jenny Seligmann: Time to re-think targeted agents in LACC/LARC

Jenny Seligmann, Professor of Gastrointestinal and Translational Oncology and Honorary Consultant in Medical Oncology at the University of Leeds, shared an article on X:

“Now online – my 2 fav topics in one paper.

FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer.
Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected patients.

Time to re-think targeted agents in LACC/LARC.”

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population.

Authors: J.F. Seligmann, et al.

Jenny Seligmann: Time to re-think targeted agents in LACC/LARC

anti-EGFR cancer Colon cancer fight against cancer Global fight against cancer Jenny Seligmann LACC LARC MedOnc Neo-adjuvant FOLFOX OncoDaily Oncology Translational Oncology University of Leeds

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage